EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PO116 | MONOCENTRIC EXPERIENCE OF DOACS REVERSAL MANAGEMENT AT L SACCO HOSPITAL, MILAN: A REAL-WORLD RETROSPECTIVE STUDY

Alessio Veltroni

Bleeding, Thrombosis and Vascular Biology · 26.10.2026 · 5 (s3)

DOI: 10.4081/btvb.2026.932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 26.10.2026. Verfasst von Alessio Veltroni. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims. The increasing use of direct oral anticoagulants (DOACs) has made the management of major bleeding and non-deferrable urgent surgery a relevant clinical challenge. Specific reversal agents are available for selected DOACs, such as andexanet alfa (AA) for factor Xa inhibitors, whereas four-factor prothrombin complex concentrate (4F-PCC) remains the most widely used non-specific option. At L. Sacco Hospital (Milan, Italy), a multidisciplinary institutional protocol based on ISTH recommendations is applied. This study aims to evaluate whether our institutional DOACs reversal strategy—based on 4F-PCC or AA—is consistent with current evidence and published case series in terms of safety and clinical outcomes.

Methods

We conducted a retrospective, single-center observational study including all consecutive DOACs reversal requests managed by the Transfusion Medicine Service (January 1, 2023 – December 31, 2025). Patients undergoing non-deferrable invasive procedures received 4F-PCC (25–50 IU/kg). Patients with intracranial hemorrhage (ICH) on apixaban or rivaroxaban received AA, while those on edoxaban or with major bleeding at other sites received 4F-PCC (25–50 IU/kg). Safety outcomes included in-hospital mortality and thrombotic events. Hemostatic effectiveness was assessed using published criteria (effective/ineffective for bleeding; ineffective/partially effective/effective for surgery), as in Khorsand et al, 2021, and Piran et al, 2018.

Results

A total of 41 reversal episodes were managed: 36 with 4F-PCC and 5 with AA. In the 4F-PCC group, hemostatic effectiveness was 82.35% in urgent surgery and 68.42% in major bleeding (p

Zitieren

APA

Veltroni, A. (2026). PO116 | MONOCENTRIC EXPERIENCE OF DOACS REVERSAL MANAGEMENT AT L SACCO HOSPITAL, MILAN: A REAL-WORLD RETROSPECTIVE STUDY. Bleeding, Thrombosis and Vascular Biology, 5(s3). https://doi.org/10.4081/btvb.2026.932

Vancouver

Veltroni A. PO116 | MONOCENTRIC EXPERIENCE OF DOACS REVERSAL MANAGEMENT AT L SACCO HOSPITAL, MILAN: A REAL-WORLD RETROSPECTIVE STUDY. Bleeding, Thrombosis and Vascular Biology. 2026;5(s3). doi:10.4081/btvb.2026.932

BibTeX
@article{Veltroni2026,
  author = {Veltroni, Alessio},
  title = {PO116 | MONOCENTRIC EXPERIENCE OF DOACS REVERSAL MANAGEMENT AT L SACCO HOSPITAL, MILAN: A REAL-WORLD RETROSPECTIVE STUDY},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  volume = {5},
  number = {s3},
  doi = {10.4081/btvb.2026.932}
}
Kostenlos starten →